Dr. Rugo on Extended Adjuvant Hormone Therapy for Breast Cancer

Hope S. Rugo, MD
Published: Monday, Jul 17, 2017



Hope S. Rugo, MD, a professor of Medicine and director of the Breast Oncology Clinical Trials Program at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses extended adjuvant hormone therapy for patients with breast cancer.

There is a substantial risk of recurrence after 5 years for patients with endocrine-sensitive HR+ breast cancer, explains Rugo. From current trials, there is still ongoing recurrence in this patient population, however those rates are lower than what was previously thought, states Rugo.
 
SELECTED
LANGUAGE


Hope S. Rugo, MD, a professor of Medicine and director of the Breast Oncology Clinical Trials Program at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses extended adjuvant hormone therapy for patients with breast cancer.

There is a substantial risk of recurrence after 5 years for patients with endocrine-sensitive HR+ breast cancer, explains Rugo. From current trials, there is still ongoing recurrence in this patient population, however those rates are lower than what was previously thought, states Rugo.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual Paris Breast Cancer Conference™Dec 31, 20181.5
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x